Get started
Author

Vanessa Buchanan

Observed names: Buchanan, Vanessa, V Buchanan, V. Buchanan
OpenAlex ID: A5063849382
New paradigms for BRCA1/BRCA2 testing in women with ovarian cancer: results of the Genetic Testing in Epithelial Ovarian Cancer (GTEOC) study
2016 · Inga Plaskocinska, Hannah Shipman, et al. · Journal of Medical Genetics · 65
PDF
The use of single armed observational data to closing the gap in otherwise disconnected evidence networks: a network meta-analysis in multiple myeloma
2018 · Susanne Schmitz, Áine Maguire, et al. · BMC Medical Research Methodology · 49
PDF
Productivity losses in patients with newly diagnosed multiple myeloma following stem cell transplantation and the impact of maintenance therapy
2019 · Graham Jackson, Jayne Galinsky, et al. · European Journal Of Haematology · 21
PDF
Anti-tumor necrosis factor treatment from diagnosis is more effective and less costly than conventional “step-up” care for patients with active Crohn’s disease: a cost-effectiveness analysis from the PROFILE trial
2025 · Nurulamin M Noor, Neil Davies, et al. · Journal of Crohn s and Colitis · 12
PDF
Relative efficacy of treatment options in transplant-ineligible newly diagnosed multiple myeloma: results from a systematic literature review and network meta-analysis
2019 · Karthik Ramasamy, Sujith Dhanasiri, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 11
PDF
Cost Effectiveness of Secukinumab for the Treatment of Active Psoriatic Arthritis in the UK
2018 · Vanessa Buchanan, Will Sullivan, et al. · PharmacoEconomics · 10
PDF
PRS6 EARLY Economic Modelling of a SMART Inhaler Exploring Cost-Effectiveness in a Severe Asthma Setting
2020 · M. Orchard, D. Alderson, et al. · Value in Health · 4
Personalised medicine for Crohn’s disease is a cost-effective strategy
2022 · Vanessa Buchanan, Susan Griffin, et al. · medRxiv · 2
PDF
A Systematic Review and Network Meta-Analysis of Maintenance Treatment for Patients with Newly Diagnosed Multiple Myeloma Post-Autologous Stem Cell Transplant
2017 · Susanne Schmitz, Vanessa Buchanan, et al. · Blood · 2
P0975 Cost-effectiveness analysis of anti-TNF treatment from diagnosis for patients with moderate and severe Crohn’s disease: an analysis using data from the PROFILE trial
2025 · N Noor, N Davies, et al. · Journal of Crohn s and Colitis · 1
Relative Efficacy of Treatment Options in Newly Diagnosed Multiple Myeloma: Results from a Systematic Literature Review and Network Meta-Analysis
2018 · Karthik Ramasamy, Howard Thom, et al. · Blood · 1
Cost-Effectiveness of Secukinumab for the Treatment of Active Psoriatic Arthritis in the UK
2017 · B Kirkham, V Buchanan, et al. · Value in Health · 1
Methods for Analysing Patient-Level Utility Data: Insights from the Literature Review and Recent NICE Technology Appraisals
2026 · Saul Stevens, Maxwell S. Barnish, et al. · PharmacoEconomics
PDF
Developing Best Practice for Analyzing Individual Patient Utility Data in Health Technology Assessment: A Modified Delphi Study
2026 · Frank Grimsey Jones, Alan Lovell, et al. · Value in Health
EE211 Cost-Effectiveness Analysis of Lebrikizumab vs. Alternative Biologics in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis in the UK
2025 · Warda Tahir, Vanessa Buchanan, et al. · Value in Health
HTA42 Better Off Dead: Mitigating For Situations Where Improving Survival Isn't Cost-Effective
2025 · Adam Costello, Vanessa Buchanan · Value in Health
P3 Cost-effectiveness analysis of anti-TNF treatment from diagnosis for patients with moderate-severe crohn’s disease: an analysis from the PROFILE trial
2025 · Nurulamin Noor, Neil Davies, et al. · Gut
Su1857: A COST-EFFECTIVENESS ANALYSIS OF ANTI-TNF TREATMENT FROM DIAGNOSIS IN PATIENTS WITH MODERATE AND SEVERE CROHN’S DISEASE: AN ANALYSIS USING DATA FROM THE PROFILE TRIAL
2025 · Nurulamin Noor, Neil Davies, et al. · Gastroenterology
High Risk Spacecraft Materials Offgassing
2024 · Vanessa Buchanan, Emmanuel Jr. Silva, et al. · International Conference on Environmental Systems (ICES)
PDF
HTA313 The Same but Different: Inconsistencies in Key Cost-Effectiveness Assumptions for Curative Therapies across Clinically Similar NICE Appraisals
2023 · V. Buchanan, W. Tahir · Value in Health
PDF
EE518 An Early Cost-Effectiveness Analysis of Minimally Invasive Paddle-Type Spinal Cord Stimulation for the Treatment of Chronic Neuropathic Pain
2022 · W Tahir, J Barker-Yip, et al. · Value in Health
POSC159 Identification of Appropriate Stroke Event and Management Costs in Atrial Fibrillation
2022 · W Tahir, J Barker-Yip, et al. · Value in Health
History of NASA's Odor Assessment (Test 6)
2022 · Greene, Benjamin, Buchanan, Vanessa, et al. · ThinkTech (Texas Tech University)
P110 Cost-effectiveness of a 17-gene classifier to guide treatment choice in Crohn’s disease in the UK
2021 · Susan Griffin, Vanessa Buchanan, et al. · Gut
PDF
PRO88 NICE Highly Specialised Technology Assessment: Has Introduction of Willingness to Pay Thresholds Impeded Positive Guidance?
2020 · V. Buchanan, W. Tahir · Value in Health
Works count: 28
Citation count: 191
H-index: 7
I10-index: 7
Year
Topic
Type